Alnylam Pharmaceuticals | ALNY - Loan Capital


Alnylam Pharmaceuticals reported $2.47B in Loan Capital for its fiscal quarter ending in June of 2026.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.47B 6.56M Jun/2026
Amgen USD 51.86B 27M Jun/2026
Arrowhead Research USD 824.07M 401.34M Jun/2026
BioCryst Pharmaceuticals USD 395.4M 203K Jun/2026
BioMarin Pharmaceutical USD 3.53B 2.1B Jun/2026
Incyte USD 28.42M 994K Jun/2026
Ionis Pharmaceuticals USD 1.91B 6.62M Jun/2026
Moderna USD 597M 6M Jun/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 37.45B 7.86B Mar/2026
PTC Therapeutics USD 535.52M 248.58M Jun/2026
Regeneron Pharmaceuticals USD 1.99B 400K Jun/2026
Sangamo BioSciences USD 0 0 Jun/2022
Sanofi EUR 12.3B 3.42B Mar/2026
Sarepta Therapeutics USD 847.62M 9.46M Jun/2026
Takeda JPY 4.42T 50.32B Jun/2026
Tectonic Therapeutic USD 17K 26K Mar/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025
Xencor USD 77.54M 4.59M Jun/2026